Mubasher: The University of Oxford launched a study to assess the safety and immune response of the Covid-19 vaccine it has developed with AstraZeneca Plc in children for the first time, CNBC reported.

The new mid-stage trial will determine whether the vaccine is effective on people aged between 6 years old and 17 years old.

Oxford said about 300 volunteers will be enrolled and first inoculations are predicted this month.

AstraZeneca seeks to produce 3 billion doses of the two-dose Oxford/AstraZeneca vaccine this year and aims to produce over 200 million doses per month by April.